History of cardiovascular disease and cardiovascular biomarkers are associated with 30-day mortality in patients with hip fracture
Summary Hip fractures are associated with increased mortality and it is important to identify risk factors. This study demonstrates that preexisting cardiovascular disease as well as cardiovascular biomarkers that are associated with increased 30-day mortality. These findings can be used to identify...
Gespeichert in:
| Veröffentlicht in: | Osteoporosis international 2019-09, Vol.30 (9), p.1767-1778 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1778 |
|---|---|
| container_issue | 9 |
| container_start_page | 1767 |
| container_title | Osteoporosis international |
| container_volume | 30 |
| creator | Norring-Agerskov, D. Madsen, C. M. Bathum, L. Pedersen, O. B. Lauritzen, J. B. Jørgensen, N. R. Jørgensen, H. L. |
| description | Summary
Hip fractures are associated with increased mortality and it is important to identify risk factors. This study demonstrates that preexisting cardiovascular disease as well as cardiovascular biomarkers that are associated with increased 30-day mortality. These findings can be used to identify high-risk patients who might benefit from specialized care.
Introduction
This study investigates the association between cardiovascular disease (CVD), cardiovascular biomarkers, and 30-day mortality following a hip fracture.
Methods
The Danish National Patient Registry was used to investigate the association between CVD and mortality following hip fracture in a nationwide population-based cohort study. In a subset of the included patients (
n
= 355), blood samples were available from a local biobank. These samples were used for analyzing the association between specific biochemical markers and mortality. The primary outcome was 30-day mortality.
Results
A total of 113,211 patients were included in the population-based cohort study. Among these, heart failure was present in 9.4%, ischemic heart disease in 15.9%, and ischemic stroke in 12.0%. Within 30 days after the hip fracture, 11,488 patients died, resulting in an overall 30-day mortality of 10.1%. The 30-day mortality was significantly increased in individuals with preexisting CVD with multivariably adjusted odds ratios of 1.69 (95% confidence interval, 1.60–1.78) for heart failure, 1.23 (1.17–1.29) for ischemic heart disease, and 1.06 (1.00–1.12) for ischemic stroke. In the local database including 355 patients, 41 (11.5%) died within 30 days. The multivariably adjusted odds ratio for 30-day mortality increased with increasing NT-proBNP (2.36 [1.53–3.64] per quartile) and decreased with increasing HDL cholesterol (0.58 [0.41–0.82] per quartile). On this basis, we established a model for predicting the probability of death based on the biochemical markers.
Conclusion
Preexisting CVD was associated with increased 30-day mortality after a hip fracture. Furthermore, high levels of NT-proBNP and low levels of HDL cholesterol were associated with increased 30-day mortality. |
| doi_str_mv | 10.1007/s00198-019-05056-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2253289861</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2252553468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-4719344121e4a7d7cee5f220b30de1fc159351ad9a8ed2afd9c7423f02e867b43</originalsourceid><addsrcrecordid>eNp9kT9vFDEQxS0EIpfAF6BAlmhoDP67XpcoAoIUiQYkutWcPUsc9taH7c3pWj45TjaAlIJmppjfezOaR8gLwd8Izu3bwrlwPWuFccNNxw6PyEZopZh0nXlMNtwpy5wW307IaSnXvImcs0_JiRLS9trKDfl1EUtN-UjTSD3kENMNFL9MkGmIBaEghTk8HG1j2kH-gblQyI0oJfkIFQM9xHpFFWcBjnSXcoUp1iONM91DjTjXshJXcU_HDL4uGZ-RJyNMBZ_f9zPy9cP7L-cX7PLzx0_n7y6ZV9ZUpq1wSmshBWqwwXpEM0rJt4oHFKMXxikjIDjoMUgYg_NWSzVyiX1nt1qdkder7z6nnwuWOuxi8ThNMGNayiClUbJ3fSca-uoBep2WPLfrbilpjNJd3yi5Uj6nUjKOwz7H9pfjIPhwm9CwJjS0MtwlNBya6OW99bLdYfgr-RNJA9QKlDaav2P-t_s_tr8BJfiedg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2252553468</pqid></control><display><type>article</type><title>History of cardiovascular disease and cardiovascular biomarkers are associated with 30-day mortality in patients with hip fracture</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Norring-Agerskov, D. ; Madsen, C. M. ; Bathum, L. ; Pedersen, O. B. ; Lauritzen, J. B. ; Jørgensen, N. R. ; Jørgensen, H. L.</creator><creatorcontrib>Norring-Agerskov, D. ; Madsen, C. M. ; Bathum, L. ; Pedersen, O. B. ; Lauritzen, J. B. ; Jørgensen, N. R. ; Jørgensen, H. L.</creatorcontrib><description>Summary
Hip fractures are associated with increased mortality and it is important to identify risk factors. This study demonstrates that preexisting cardiovascular disease as well as cardiovascular biomarkers that are associated with increased 30-day mortality. These findings can be used to identify high-risk patients who might benefit from specialized care.
Introduction
This study investigates the association between cardiovascular disease (CVD), cardiovascular biomarkers, and 30-day mortality following a hip fracture.
Methods
The Danish National Patient Registry was used to investigate the association between CVD and mortality following hip fracture in a nationwide population-based cohort study. In a subset of the included patients (
n
= 355), blood samples were available from a local biobank. These samples were used for analyzing the association between specific biochemical markers and mortality. The primary outcome was 30-day mortality.
Results
A total of 113,211 patients were included in the population-based cohort study. Among these, heart failure was present in 9.4%, ischemic heart disease in 15.9%, and ischemic stroke in 12.0%. Within 30 days after the hip fracture, 11,488 patients died, resulting in an overall 30-day mortality of 10.1%. The 30-day mortality was significantly increased in individuals with preexisting CVD with multivariably adjusted odds ratios of 1.69 (95% confidence interval, 1.60–1.78) for heart failure, 1.23 (1.17–1.29) for ischemic heart disease, and 1.06 (1.00–1.12) for ischemic stroke. In the local database including 355 patients, 41 (11.5%) died within 30 days. The multivariably adjusted odds ratio for 30-day mortality increased with increasing NT-proBNP (2.36 [1.53–3.64] per quartile) and decreased with increasing HDL cholesterol (0.58 [0.41–0.82] per quartile). On this basis, we established a model for predicting the probability of death based on the biochemical markers.
Conclusion
Preexisting CVD was associated with increased 30-day mortality after a hip fracture. Furthermore, high levels of NT-proBNP and low levels of HDL cholesterol were associated with increased 30-day mortality.</description><identifier>ISSN: 0937-941X</identifier><identifier>EISSN: 1433-2965</identifier><identifier>DOI: 10.1007/s00198-019-05056-w</identifier><identifier>PMID: 31278472</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Aged ; Aged, 80 and over ; Algorithms ; Biochemical markers ; Biomarkers ; Biomarkers - blood ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - complications ; Cardiovascular Diseases - mortality ; Cholesterol ; Congestive heart failure ; Coronary artery disease ; Denmark - epidemiology ; Endocrinology ; Female ; Fractures ; Health risk assessment ; Heart failure ; High density lipoprotein ; Hip ; Hip Fractures - blood ; Hip Fractures - complications ; Hip Fractures - mortality ; Humans ; Ischemia ; Kaplan-Meier Estimate ; Lipids - blood ; Male ; Medicine ; Medicine & Public Health ; Mortality ; Natriuretic Peptide, Brain - blood ; Odds Ratio ; Original Article ; Orthopedics ; Osteoporotic Fractures - blood ; Osteoporotic Fractures - complications ; Osteoporotic Fractures - mortality ; Peptide Fragments - blood ; Population studies ; Prognosis ; Registries ; Rheumatology ; Risk Assessment - methods ; Risk Factors ; Risk groups ; Troponin I - blood</subject><ispartof>Osteoporosis international, 2019-09, Vol.30 (9), p.1767-1778</ispartof><rights>International Osteoporosis Foundation and National Osteoporosis Foundation 2019</rights><rights>Osteoporosis International is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-4719344121e4a7d7cee5f220b30de1fc159351ad9a8ed2afd9c7423f02e867b43</citedby><cites>FETCH-LOGICAL-c375t-4719344121e4a7d7cee5f220b30de1fc159351ad9a8ed2afd9c7423f02e867b43</cites><orcidid>0000-0003-1025-6205</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00198-019-05056-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00198-019-05056-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31278472$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Norring-Agerskov, D.</creatorcontrib><creatorcontrib>Madsen, C. M.</creatorcontrib><creatorcontrib>Bathum, L.</creatorcontrib><creatorcontrib>Pedersen, O. B.</creatorcontrib><creatorcontrib>Lauritzen, J. B.</creatorcontrib><creatorcontrib>Jørgensen, N. R.</creatorcontrib><creatorcontrib>Jørgensen, H. L.</creatorcontrib><title>History of cardiovascular disease and cardiovascular biomarkers are associated with 30-day mortality in patients with hip fracture</title><title>Osteoporosis international</title><addtitle>Osteoporos Int</addtitle><addtitle>Osteoporos Int</addtitle><description>Summary
Hip fractures are associated with increased mortality and it is important to identify risk factors. This study demonstrates that preexisting cardiovascular disease as well as cardiovascular biomarkers that are associated with increased 30-day mortality. These findings can be used to identify high-risk patients who might benefit from specialized care.
Introduction
This study investigates the association between cardiovascular disease (CVD), cardiovascular biomarkers, and 30-day mortality following a hip fracture.
Methods
The Danish National Patient Registry was used to investigate the association between CVD and mortality following hip fracture in a nationwide population-based cohort study. In a subset of the included patients (
n
= 355), blood samples were available from a local biobank. These samples were used for analyzing the association between specific biochemical markers and mortality. The primary outcome was 30-day mortality.
Results
A total of 113,211 patients were included in the population-based cohort study. Among these, heart failure was present in 9.4%, ischemic heart disease in 15.9%, and ischemic stroke in 12.0%. Within 30 days after the hip fracture, 11,488 patients died, resulting in an overall 30-day mortality of 10.1%. The 30-day mortality was significantly increased in individuals with preexisting CVD with multivariably adjusted odds ratios of 1.69 (95% confidence interval, 1.60–1.78) for heart failure, 1.23 (1.17–1.29) for ischemic heart disease, and 1.06 (1.00–1.12) for ischemic stroke. In the local database including 355 patients, 41 (11.5%) died within 30 days. The multivariably adjusted odds ratio for 30-day mortality increased with increasing NT-proBNP (2.36 [1.53–3.64] per quartile) and decreased with increasing HDL cholesterol (0.58 [0.41–0.82] per quartile). On this basis, we established a model for predicting the probability of death based on the biochemical markers.
Conclusion
Preexisting CVD was associated with increased 30-day mortality after a hip fracture. Furthermore, high levels of NT-proBNP and low levels of HDL cholesterol were associated with increased 30-day mortality.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Algorithms</subject><subject>Biochemical markers</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - complications</subject><subject>Cardiovascular Diseases - mortality</subject><subject>Cholesterol</subject><subject>Congestive heart failure</subject><subject>Coronary artery disease</subject><subject>Denmark - epidemiology</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Fractures</subject><subject>Health risk assessment</subject><subject>Heart failure</subject><subject>High density lipoprotein</subject><subject>Hip</subject><subject>Hip Fractures - blood</subject><subject>Hip Fractures - complications</subject><subject>Hip Fractures - mortality</subject><subject>Humans</subject><subject>Ischemia</subject><subject>Kaplan-Meier Estimate</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mortality</subject><subject>Natriuretic Peptide, Brain - blood</subject><subject>Odds Ratio</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Osteoporotic Fractures - blood</subject><subject>Osteoporotic Fractures - complications</subject><subject>Osteoporotic Fractures - mortality</subject><subject>Peptide Fragments - blood</subject><subject>Population studies</subject><subject>Prognosis</subject><subject>Registries</subject><subject>Rheumatology</subject><subject>Risk Assessment - methods</subject><subject>Risk Factors</subject><subject>Risk groups</subject><subject>Troponin I - blood</subject><issn>0937-941X</issn><issn>1433-2965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kT9vFDEQxS0EIpfAF6BAlmhoDP67XpcoAoIUiQYkutWcPUsc9taH7c3pWj45TjaAlIJmppjfezOaR8gLwd8Izu3bwrlwPWuFccNNxw6PyEZopZh0nXlMNtwpy5wW307IaSnXvImcs0_JiRLS9trKDfl1EUtN-UjTSD3kENMNFL9MkGmIBaEghTk8HG1j2kH-gblQyI0oJfkIFQM9xHpFFWcBjnSXcoUp1iONM91DjTjXshJXcU_HDL4uGZ-RJyNMBZ_f9zPy9cP7L-cX7PLzx0_n7y6ZV9ZUpq1wSmshBWqwwXpEM0rJt4oHFKMXxikjIDjoMUgYg_NWSzVyiX1nt1qdkder7z6nnwuWOuxi8ThNMGNayiClUbJ3fSca-uoBep2WPLfrbilpjNJd3yi5Uj6nUjKOwz7H9pfjIPhwm9CwJjS0MtwlNBya6OW99bLdYfgr-RNJA9QKlDaav2P-t_s_tr8BJfiedg</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Norring-Agerskov, D.</creator><creator>Madsen, C. M.</creator><creator>Bathum, L.</creator><creator>Pedersen, O. B.</creator><creator>Lauritzen, J. B.</creator><creator>Jørgensen, N. R.</creator><creator>Jørgensen, H. L.</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1025-6205</orcidid></search><sort><creationdate>20190901</creationdate><title>History of cardiovascular disease and cardiovascular biomarkers are associated with 30-day mortality in patients with hip fracture</title><author>Norring-Agerskov, D. ; Madsen, C. M. ; Bathum, L. ; Pedersen, O. B. ; Lauritzen, J. B. ; Jørgensen, N. R. ; Jørgensen, H. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-4719344121e4a7d7cee5f220b30de1fc159351ad9a8ed2afd9c7423f02e867b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Algorithms</topic><topic>Biochemical markers</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - complications</topic><topic>Cardiovascular Diseases - mortality</topic><topic>Cholesterol</topic><topic>Congestive heart failure</topic><topic>Coronary artery disease</topic><topic>Denmark - epidemiology</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Fractures</topic><topic>Health risk assessment</topic><topic>Heart failure</topic><topic>High density lipoprotein</topic><topic>Hip</topic><topic>Hip Fractures - blood</topic><topic>Hip Fractures - complications</topic><topic>Hip Fractures - mortality</topic><topic>Humans</topic><topic>Ischemia</topic><topic>Kaplan-Meier Estimate</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mortality</topic><topic>Natriuretic Peptide, Brain - blood</topic><topic>Odds Ratio</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Osteoporotic Fractures - blood</topic><topic>Osteoporotic Fractures - complications</topic><topic>Osteoporotic Fractures - mortality</topic><topic>Peptide Fragments - blood</topic><topic>Population studies</topic><topic>Prognosis</topic><topic>Registries</topic><topic>Rheumatology</topic><topic>Risk Assessment - methods</topic><topic>Risk Factors</topic><topic>Risk groups</topic><topic>Troponin I - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Norring-Agerskov, D.</creatorcontrib><creatorcontrib>Madsen, C. M.</creatorcontrib><creatorcontrib>Bathum, L.</creatorcontrib><creatorcontrib>Pedersen, O. B.</creatorcontrib><creatorcontrib>Lauritzen, J. B.</creatorcontrib><creatorcontrib>Jørgensen, N. R.</creatorcontrib><creatorcontrib>Jørgensen, H. L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Osteoporosis international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Norring-Agerskov, D.</au><au>Madsen, C. M.</au><au>Bathum, L.</au><au>Pedersen, O. B.</au><au>Lauritzen, J. B.</au><au>Jørgensen, N. R.</au><au>Jørgensen, H. L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>History of cardiovascular disease and cardiovascular biomarkers are associated with 30-day mortality in patients with hip fracture</atitle><jtitle>Osteoporosis international</jtitle><stitle>Osteoporos Int</stitle><addtitle>Osteoporos Int</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>30</volume><issue>9</issue><spage>1767</spage><epage>1778</epage><pages>1767-1778</pages><issn>0937-941X</issn><eissn>1433-2965</eissn><abstract>Summary
Hip fractures are associated with increased mortality and it is important to identify risk factors. This study demonstrates that preexisting cardiovascular disease as well as cardiovascular biomarkers that are associated with increased 30-day mortality. These findings can be used to identify high-risk patients who might benefit from specialized care.
Introduction
This study investigates the association between cardiovascular disease (CVD), cardiovascular biomarkers, and 30-day mortality following a hip fracture.
Methods
The Danish National Patient Registry was used to investigate the association between CVD and mortality following hip fracture in a nationwide population-based cohort study. In a subset of the included patients (
n
= 355), blood samples were available from a local biobank. These samples were used for analyzing the association between specific biochemical markers and mortality. The primary outcome was 30-day mortality.
Results
A total of 113,211 patients were included in the population-based cohort study. Among these, heart failure was present in 9.4%, ischemic heart disease in 15.9%, and ischemic stroke in 12.0%. Within 30 days after the hip fracture, 11,488 patients died, resulting in an overall 30-day mortality of 10.1%. The 30-day mortality was significantly increased in individuals with preexisting CVD with multivariably adjusted odds ratios of 1.69 (95% confidence interval, 1.60–1.78) for heart failure, 1.23 (1.17–1.29) for ischemic heart disease, and 1.06 (1.00–1.12) for ischemic stroke. In the local database including 355 patients, 41 (11.5%) died within 30 days. The multivariably adjusted odds ratio for 30-day mortality increased with increasing NT-proBNP (2.36 [1.53–3.64] per quartile) and decreased with increasing HDL cholesterol (0.58 [0.41–0.82] per quartile). On this basis, we established a model for predicting the probability of death based on the biochemical markers.
Conclusion
Preexisting CVD was associated with increased 30-day mortality after a hip fracture. Furthermore, high levels of NT-proBNP and low levels of HDL cholesterol were associated with increased 30-day mortality.</abstract><cop>London</cop><pub>Springer London</pub><pmid>31278472</pmid><doi>10.1007/s00198-019-05056-w</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-1025-6205</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-941X |
| ispartof | Osteoporosis international, 2019-09, Vol.30 (9), p.1767-1778 |
| issn | 0937-941X 1433-2965 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2253289861 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Aged Aged, 80 and over Algorithms Biochemical markers Biomarkers Biomarkers - blood Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - blood Cardiovascular Diseases - complications Cardiovascular Diseases - mortality Cholesterol Congestive heart failure Coronary artery disease Denmark - epidemiology Endocrinology Female Fractures Health risk assessment Heart failure High density lipoprotein Hip Hip Fractures - blood Hip Fractures - complications Hip Fractures - mortality Humans Ischemia Kaplan-Meier Estimate Lipids - blood Male Medicine Medicine & Public Health Mortality Natriuretic Peptide, Brain - blood Odds Ratio Original Article Orthopedics Osteoporotic Fractures - blood Osteoporotic Fractures - complications Osteoporotic Fractures - mortality Peptide Fragments - blood Population studies Prognosis Registries Rheumatology Risk Assessment - methods Risk Factors Risk groups Troponin I - blood |
| title | History of cardiovascular disease and cardiovascular biomarkers are associated with 30-day mortality in patients with hip fracture |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T06%3A12%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=History%20of%20cardiovascular%20disease%20and%20cardiovascular%20biomarkers%20are%20associated%20with%2030-day%20mortality%20in%20patients%20with%20hip%20fracture&rft.jtitle=Osteoporosis%20international&rft.au=Norring-Agerskov,%20D.&rft.date=2019-09-01&rft.volume=30&rft.issue=9&rft.spage=1767&rft.epage=1778&rft.pages=1767-1778&rft.issn=0937-941X&rft.eissn=1433-2965&rft_id=info:doi/10.1007/s00198-019-05056-w&rft_dat=%3Cproquest_cross%3E2252553468%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2252553468&rft_id=info:pmid/31278472&rfr_iscdi=true |